Form 4: CRISPR Therapeutics CEO Samarth Kulkarni Reports Stock Transactions
SEC Form 4
CEO Samarth Kulkarni reports acquisition and disposal of CRISPR Therapeutics shares related to vesting of restricted stock units and tax obligations.
Summary
- On October 13, 2024, Samarth Kulkarni, CEO of CRISPR Therapeutics, acquired 8,333 common shares through the vesting of restricted stock units.
- On October 14, 2024, Kulkarni disposed of 4,293 common shares at a price of $46.28 to cover tax withholding obligations related to the vesting of the restricted stock units.
- Following these transactions, Kulkarni directly owns 226,540 common shares and indirectly owns 85,622 shares through The Kulkarni 2023 GRAT.
- The restricted stock units were granted on October 13, 2023, and vest in three equal installments on October 13, 2024, October 13, 2025, and October 13, 2026.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are routine and related to executive compensation and tax obligations. There is no indication of unusual activity or concern.
Positives
- The vesting of restricted stock units indicates a continued alignment of the CEO's interests with those of the shareholders.
Industry Context
Stock transactions by company executives are routinely monitored by investors as they can provide insights into management's confidence in the company's future prospects. The vesting of restricted stock units is a common form of executive compensation in the biotechnology industry.
Comparison to Industry Standards
- Executive compensation packages in biotech often include restricted stock units that vest over several years to align management's interests with long-term shareholder value.
- Companies like Vertex Pharmaceuticals and BioMarin Pharmaceutical also utilize similar equity-based compensation strategies for their executives.
- The vesting schedule of CRISPR Therapeutics' restricted stock units is fairly standard, with one-third vesting annually over a three-year period.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they involve the CEO's personal holdings and tax obligations.
Key Dates
| Date | Description |
|---|---|
| October 13, 2023 | Date of grant for restricted stock units. |
| October 13, 2024 | Vesting date for the first tranche of restricted stock units; acquisition of 8,333 shares. |
| October 14, 2024 | Sale of 4,293 shares to cover tax obligations. |
| October 13, 2025 | Vesting date for the second tranche of restricted stock units. |
| October 13, 2026 | Vesting date for the third tranche of restricted stock units. |
| October 15, 2024 | Date of the report filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.